{"name":"Per Pfeiffer","slug":"per-pfeiffer","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"DOS2w Dose level 3A","genericName":"DOS2w Dose level 3A","slug":"dos2w-dose-level-3a","indication":"Other","status":"phase_1"},{"name":"DOS3w Dose level 1B","genericName":"DOS3w Dose level 1B","slug":"dos3w-dose-level-1b","indication":"Other","status":"phase_1"},{"name":"Oxaliplatin, irinotecan, 5-FU & leucovorin","genericName":"Oxaliplatin, irinotecan, 5-FU & leucovorin","slug":"oxaliplatin-irinotecan-5-fu-leucovorin","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"DOS2w Dose level 3A","genericName":"DOS2w Dose level 3A","slug":"dos2w-dose-level-3a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DOS3w Dose level 1B","genericName":"DOS3w Dose level 1B","slug":"dos3w-dose-level-1b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Oxaliplatin, irinotecan, 5-FU & leucovorin","genericName":"Oxaliplatin, irinotecan, 5-FU & leucovorin","slug":"oxaliplatin-irinotecan-5-fu-leucovorin","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNVHlZdlctNDBETDNzQm93ZE5Dd0lLaFlTb3hWOTVoR2NCM1FWdFZ1WFV6QTF4ZG8yVTdUYnZtUFBPWEVTbnRUNGUxSkQ0RlpMN2NpZnR1Ml9VMC1pUmpaQlprekdxY3psams0ZVpEUXZMODZJYVV4U3dnVHV2WkxzTVdKZFNSUS1NUlRkZGl3T3VNUlpnTF85UWFkWlRLWVRMNkgzRzNGc3pDbU5DWHdOdksxYkQ?oc=5","date":"2025-01-29","type":"pipeline","source":"RealClearHealth","summary":"Fight Knee-Jerk: Robert F. Kennedy May Surprise You - RealClearHealth","headline":"Fight Knee-Jerk: Robert F. Kennedy May Surprise You","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOV3pIUVBTcDJ3SHBCNWpKbmZSNW55UDh2aVJaNnBfYkl6OHQ5MGk4eG9jOUQ1VjhtZFNadnlaSjExVnhPalFGbHRCUmdWMVpjR3d5ZDBuREQ4eFNsa0hPelJoU0VNWnd4OGE4R0VDVWVGdTBxcl82TG9PSVpyMW5WYkxpRXpYcURSbFZmMmgtd1R4dHd5WFd1R09hR0pPcU5RaXZFS0xRcHNQM01oaTdQMV95TXlPcVZkMEJYdzF2c2RLcl96NGJz?oc=5","date":"2025-01-09","type":"deal","source":"McKinsey & Company","summary":"Building a shared vision for pharma R&D–supplier partnerships - McKinsey & Company","headline":"Building a shared vision for pharma R&D–supplier partnerships - McKinsey & Company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOQm1VYkp6WW5lSWpxdnA5VzZvYTRXU0cyQXgzRGZhUG1aNGN4ak9NQWU4SzVkNjBabUlqUFRtTnVsRm5NbGphVEE4c19xY3I2WG1ZUkFkcU1qV0o0YzBRLWJqNnJ4cUVRclRGUDFhR25mbnFlSVJfMGlVdDFFUjE0eDlWV0txb1lncXM4UWNGWWprNmxmMkZGV1dSZ0ViT2JBZ2hyZlVoY21YbVFQTDA0TmY3dW96UHZsSkE?oc=5","date":"2022-06-29","type":"pipeline","source":"Calgary Herald","summary":"Parker: Celebrating the indefatigable Irene Pfeiffer - Calgary Herald","headline":"Parker: Celebrating the indefatigable Irene Pfeiffer","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":2,"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}